In this study, 24% of UC patients harbored pathogenic germline variants and 18.6% had clinically actionable variants. MLH1 and MSH2 were validated as UC risk genes while ATM and BRCA2 were highlighted as potential UC predisposition genes. This work emphasizes the utility of germline testing in selec …
Read it now on PracticeUpdate.com
A video from Guru Sonpavde (as part of Oncology 2024 Year in Review), posted on Dec 2, 2024.
A video from Guru Sonpavde (as part of 2024 ESMO Annual Meeting Insights Hub), posted on Sep 24, 2024.
The CloudCME® learning management system (LMS) provides application, registration, evaluation, certificate, transcript, faculty, scheduling and disclosure collection & PARS, NARS & CPEMonitor reporting in one…
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
Read it now on PracticeUpdate.com
The CloudCME® learning management system (LMS) provides application, registration, evaluation, certificate, transcript, faculty, scheduling and disclosure collection & PARS, NARS & CPEMonitor reporting in one…
A video from Guru Sonpavde (as part of 2024 ASCO® Annual Meeting Insights Hub), posted on Jul 5, 2024.
While there were no practice-changing bladder urothelial carcinoma (UC) data, the 2024 ASCO annual conference yielded practice-informing advances. …
